| Similar Articles |
|---|
 |
The Motley Fool
May 25, 2005
Karl Thiel |
A Gold Mine in Generics Will NitroMed's new math add up to investment success?   |
The Motley Fool
April 8, 2004
W.D. Crotty |
A Bet on Taser Taser has climbed to dizzying heights but there are options. |
The Motley Fool
April 20, 2004
W.D. Crotty |
As the Taser Turns This is a rough day, but Taser is still up 5,000% over the last 52 weeks. |
The Motley Fool
April 6, 2004
W.D. Crotty |
CBS Zaps Taser CBS News investigates the safety of Taser's weapons. What will this do for the stock? |
The Motley Fool
September 15, 2004
W.D. Crotty |
Is This Taser for You? Get ready for the new personal-use stun gun. It may just be right for you. But if you are looking for a stock ready to explode when it is discovered, Taser is not for you. |
The Motley Fool
June 16, 2005
Karl Thiel |
BiDil's Bid for a Narrow Label Although things appear to be going NitroMed's way, there is a dark horse spoiler looming in the shadows that should keep investors on their toes today. The company is seeking FDA approval for African-Americans only, but what if BiDil is given a broader label acceptance? |
The Motley Fool
July 20, 2004
W.D. Crotty |
When to Sell Taser Embattled would be a great word to describe non-lethal weapon manufacturer Taser. The latest battle is with the New York Times. When is the right time to sell the stock? |
The Motley Fool
May 3, 2004
W.D. Crotty |
What to Make of Taser? It's easy to question but hard to predict Taser's long-term potential. |
The Motley Fool
February 13, 2004
W.D. Crotty |
Taser's a Real Stunner Believe it or not, high-flying Taser may yet have room to fly. It's an increasingly unpopular position, but there's at least one person who's not convinced that upstart Taser International is some overpriced story stock. |
The Motley Fool
June 21, 2004
W.D. Crotty |
Love That Taser Taser raises revenue guidance by 50%. |
Bio-IT World
January 21, 2005 |
The Race Prescription Card The FDA is on the verge of approving a heart disease drug called BiDil that is particularly effective in African-Americans. Some see this as a an effort to address health inequalities while others view it as a first step en route to racial discrimination. |
The Motley Fool
February 3, 2004
Jeff Hwang |
Taser Shocks Shorts With over half its float sold short, Taser delivers explosive growth. |
The Motley Fool
July 29, 2005
Tim Beyers |
Readers: Taser Worth the Risk Last week, we asked whether Taser's mounting legal problems creates too much risk for investors. This week we go through your responses. The verdict? Taser is the future. |
Bio-IT World
April 2006
Kevin Davies |
NitroMed Ties Gene Biomarkers to BiDil Benefit The FDA approval of BiDil, NitroMed's heart failure drug for blacks, raised howls of controversy. Now at a meeting of the American College of Cardiology, researchers presented two papers that offer the first preliminary hints of genetic factors that affect BiDil response. |
The Motley Fool
January 16, 2004
Seth Jayson |
Taser on a Tear Stun-gun maker's rampage continues, most recently on a stock-split announcement. |
The Motley Fool
February 13, 2004
Jeff Hwang |
Taser's Split Madness Stock splits don't create value, but try telling that to Taser investors. |
The Motley Fool
October 19, 2004
W.D. Crotty |
To Those Who Hate Taser The weapons company reports another stellar quarter. |
The Motley Fool
June 16, 2005
Chuck Saletta |
Dueling Fools: Taser Bear Even having lost two-thirds of its market cap since its peak, stun-gun manufacturer Taser is still no value. |
The Motley Fool
June 10, 2004
Seth Jayson |
Three Early Summer Sizzlers A few stocks worth watching, if only for the heated drama. |
The Motley Fool
November 5, 2004
W.D. Crotty |
Taser for Half the Price For the third time this year, the company is splitting its stock. |
The Motley Fool
December 21, 2004
Alyce Lomax |
Taser Shocks Stinger The stun gun maker delivers a lawsuit to a would-be rival. What with Taser's recent meteoric rise, it's no surprise the fight is on to keep would-be competitors at bay. |
BusinessWeek
June 27, 2005
Amy Barrett |
Color-Blind Drug Research Is Myopic Researchers will sometimes have to use the blunt instrument of race to help match patients with the right drugs. |
The Motley Fool
June 16, 2005
Seth Jayson |
Dueling Fools: Taser Bull By the numbers, Taser won't make sense. But you should look beyond the numbers. If you can stomach a wild ride, and you want a dose of risky-but-explosive potential in your portfolio, Taser is one of a kind. |
The Motley Fool
December 14, 2004
Brian Gorman |
Bristol-Myers' Smart Moves Although problems still hang over the company, Bristol-Myers is paving the way for recovery. In the meantime investors will surely be jittery. |
The Motley Fool
April 25, 2006
Jim Mueller |
Foolish Forecast: TASER's Turning Point? TASER International reports earnings for first-quarter 2006. After falling from its highs of late 2004 and spending the past six months climbing up from its recent lows, the company hopes it can really surprise investors with a good earnings report. |
The Motley Fool
January 21, 2005
Seth Jayson |
Mum's the Word at Taser Taser notifies cops that it needs to up the power in its flagship product. Why weren't investors told? |
The Motley Fool
July 20, 2005
W.D. Crotty |
Taser Turns Up the Juice Taser is a strong company with increasing international growth. However, with all its legal battles and bad press, investors may rightly wonder when its profitability will return in a meaningful way. |
The Motley Fool
August 7, 2008
Mac Greer |
Fool Video: Buy, Sell, or Hold Taser? Shares of TASER are trading near their 52-week lows. What does the future hold for the company? That question is discussed in this video. |
The Motley Fool
May 1, 2006
Jim Mueller |
TASER: Great PR, Middling Quarter In a full-court PR press, TASER reported mixed results. Wise investors shouldn't jump in quite yet. |
The Motley Fool
July 1, 2005
Rick Aristotle Munarriz |
Taser Stuns Media The stun-gun specialist fires a lawsuit at Gannett. While it would be naive to think that some of the stock's decline was not the result of the company's own handiwork, it's hard to deny that the media has influenced public perception of Taser. |
The Motley Fool
December 16, 2004
Paul Elliott |
Do You Have the Guts to Buy? Growth investing is best served by a knack for spotting those rare birds that change the world -- and having the nerve to buy them when you do. But can it be done? You can't argue with success. |
